Elevation Oncology to Shine at Investment Conference
Elevation Oncology, Inc. (NASDAQ: ELEV) is set to highlight its innovative advancements in oncology at the prestigious H.C. Wainwright 26th Annual Global Investment Conference. This important event brings together key investors and industry leaders who are interested in groundbreaking healthcare solutions that tackle some of the most urgent challenges in the field.
Conference Details
Joseph J. Ferra, the Chief Executive Officer of Elevation Oncology, will engage in a fireside chat addressing vital topics related to the future of cancer treatment. This presentation is scheduled for an upcoming Tuesday at 11:30 am ET. Investors and stakeholders looking for insights can anticipate valuable discussions about Elevation’s cutting-edge therapies.
Event Accessibility
The event will be available through a live webcast, making it easy for those interested in Elevation Oncology’s initiatives to participate. Additionally, a replay will be accessible for anyone who cannot attend live, providing a great opportunity for information sharing and engagement.
Webcast Details
To watch the event, viewers can visit the Company's Investor Relations website, where the webcast will be hosted. Staying informed about these developments is essential for anyone following Elevation Oncology's progress in cancer therapy innovation.
Elevation Oncology's Mission and Focus
Elevation Oncology is dedicated to pioneering selective cancer therapies that meet patient needs across a range of solid tumors. The company is particularly focused on developing novel antibody-drug conjugates (ADCs) to address significant medical areas that are currently underserved.
Innovative Pipeline
The company is advancing a distinctive pipeline that targets clinically validated areas in oncology, specifically focusing on Claudin 18.2 and HER3, which are relevant in various cancers. The lead candidate, EO-3021, is gaining attention as it is designed to be a best-in-class ADC.
Current Trials and Future Prospects
EO-3021 is currently being evaluated in a Phase 1 trial involving patients diagnosed with advanced, unresectable, or metastatic solid tumors likely to express Claudin 18.2, including gastric and pancreatic cancers. Exciting developments are anticipated as the company prepares to announce a development candidate targeting HER3 in 2024.
Broader Impact of Elevation Oncology
With a mission focused on benefiting patients, Elevation Oncology is committed to transforming the landscape of oncology. The company’s innovative strategies have the potential to significantly improve treatment outcomes for patients facing some of the most challenging cancers.
Ongoing Commitment to Research
Research and development are at the heart of Elevation's operations. By continually investing in their ADC platform and committing to clinical validation, they remain leaders in oncology innovation. Elevation’s efforts aim not only to enhance medication efficacy but also to contribute significantly to the overall understanding and management of cancer treatment.
Engagement with the Community
Elevation Oncology's participation in conferences like the H.C. Wainwright event helps to boost its visibility. By engaging with investors, the company fosters essential partnerships for growth, shaping the future of oncology. For more information about Elevation and its advancements, visitors can explore their official website at www.ElevationOncology.com.
Investor and Media Contact Information
If you have inquiries related to investor relations or media requests, please contact Hannah Deresiewicz, EVP and Managing Director at Precision AQ, using the following details:
Phone: 212-362-1200
Email: [email protected]
Frequently Asked Questions
What is the main focus of Elevation Oncology?
Elevation Oncology is dedicated to developing selective cancer therapies that target various solid tumors, addressing significant unmet medical needs.
When will Joseph J. Ferra be speaking?
Joseph J. Ferra will be speaking during a fireside chat on Tuesday at 11:30 am ET at the H.C. Wainwright Conference.
How can I watch the presentation live?
The presentation will be available through a live webcast on the Company's Investor Relations website.
What is EO-3021?
EO-3021 is Elevation Oncology's lead ADC candidate aimed at Claudin 18.2, which is currently being evaluated in Phase 1 trials.
What is next for Elevation Oncology?
Elevation Oncology is planning to nominate a development candidate for a HER3-targeting ADC in 2024, further expanding their innovative pipeline.